RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Tenosynovial Giant Cell Tumour: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Efficacy and Safety of CSF1R Inhibitors for Recurrent or Unresectable Tenosynovial Giant Cell Tumor: A Systematic Review and Meta-Analysis of Phase III Randomized Controlled Trials.
Ahmad Mehmood et al., Asia-Pacific journal of clinical oncology (16 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42885516/
- 2.
Pimicotinib versus placebo in tenosynovial giant cell tumor (TGCT): a plain language summary of the MANEUVER clinical trial.
Gelderblom Hans et al., Future oncology (London, England) (14 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42872549/
- 3.
Clinicopathological Profile of Giant Cell Tumor of Tendon Sheath: A Case Series of Four Patients
Shashikumar Rathod et al., NATIONAL BOARD OF EXAMINATIONS JOURNAL OF MEDICAL SCIENCES (6 October 2026)
https://doi.org/10.61770/nbejms.2026.v04.i10.019
- 4.
Revision Total Knee Arthroplasty in a Case of Operated Right Total Knee Arthroplasty with Implant Loosening and Pigmented Villonodular Synovitis.
Satvilkar Mohd Zafer Noor Mohd et al., Journal of orthopaedic case reports (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42851641/
- 5.
[Tenosyovial giant cell tumor (TGCT): From the physiopathology to the emergence of new targeted therapies].
Firmin Nelly et al., Bulletin du cancer (17 September 2026)
https://pubmed.ncbi.nlm.nih.gov/42754413/
Clinical Trials : Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT
NCT05349643 · Completed · Phase 2 · AmMax Bio, Inc.
Ages 18 and over
https://clinicaltrials.gov/study/NCT05349643
- 2.
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
NCT05059262 · Active (not recruiting) · Phase 3 · Deciphera Pharmaceuticals, LLC
Ages 18 and over
https://clinicaltrials.gov/study/NCT05059262
- 3.
Study to Evaluate Discontinuation and Re-Treatment in Participants With Tenosynovial Giant Cell Tumor (TGCT) Previously Treated With Pexidartinib
NCT04526704 · Completed · Phase 4 · Daiichi Sankyo
Ages 18 and over
https://clinicaltrials.gov/study/NCT04526704
- 4.
Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor
NCT03069469 · Active (not recruiting) · Phase 1 / Phase 2 · Deciphera Pharmaceuticals, LLC
Ages 18 and over
https://clinicaltrials.gov/study/NCT03069469
- 5.
Phase 3 Study of Pexidartinib for Pigmented Villonodular Synovitis (PVNS) or Giant Cell Tumor of the Tendon Sheath (GCT-TS)
NCT02371369 · Completed · Phase 3 · Daiichi Sankyo
Ages 18 and over
https://clinicaltrials.gov/study/NCT02371369
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Tenosynovial Giant Cell Tumour
Tenosynovial Giant Cell Tumour (TGCT) is a rare, locally aggressive tumour arising from the synovial tissue of joints, tendon sheaths, and bursae. It occurs in two subtypes: localised (a tumour with a distinct, contained boundary) and diffuse (infiltrative growth without a clear boundary, which can destroy surrounding cartilage and bone). The diffuse subtype frequently recurs after surgery. Targeted therapies blocking the CSF1/CSF1R pathway have become an important treatment option for disease that cannot be fully removed surgically.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
AIM: Tenosynovial giant cell tumor (TGCT) is a rare, locally aggressive neoplasm driven by overexpression of colony-stimulating factor 1 (CSF1). We performed a meta-analysis of the efficacy and safety of CSF1 receptor inhibitors (CSF1Ri) versus placebo in recurrent or unresectable TGCT, defined as symptomatic disease for which surgery would cause worsening functional limitation or severe morbidity. METHODS: PubMed/MEDLINE, Scopus, Google Scholar, CENTRAL, and the ClinicalTrials.gov registry were searched from inception to March 25, 2026 for phase III randomized controlled trials (RCTs) comparing any CSF1Ri with placebo in adults with histologically confirmed TGCT. The primary outcome was objective response rate (ORR); secondary outcomes were physical function (PROMIS-PF), range of motion (ROM), pain, health-related quality of life (EQ-VAS), and Grade 3 or higher adverse events. Risk of bias (RoB 2) and certainty (GRADE) were assessed; estimates were pooled using random-effects models (RevMan 5.4.1), with fixed-effect, Hartung-Knapp-Sidik-Jonkman, risk-difference, and leave-one-out sensitivity analyses. RESULTS: Three RCTs were included (ENLIVEN, MOTION, MANEUVER; n = 337), all at low risk of bias. CSF1Ri significantly improved ORR (RR 25.55 [95% CI 6.43-101.52]; risk difference 0.43 [0.36-0.50]), PROMIS-PF (MD 3.81 [2.28-5.34]), relative ROM (MD 11.43 [6.53-16.34] percentage points), and EQ-VAS (MD 7.63 [4.03-11.23]) (all I2 = 0%, p < 0.001), and reduced pain (SMD -1.03 [-1.65 to -0.42]; p = 0.0009; I2 = 76%). Grade 3 or higher adverse events were more frequent with CSF1Ri (RR 4.08 [2.31-7.21]; p < 0.001; I2 = 0%). Certainty was high for functional outcomes, moderate for ORR and Grade 3 or higher adverse events, and low for pain. CONCLUSIONS: In recurrent or unresectable TGCT, CSF1Ri produce clinically meaningful improvements in tumor response, function, and quality of life compared with placebo, at the cost of more frequent severe adverse events, the nature of which differed between trials. The included trials did not compare agents directly, so the relative efficacy and safety of individual CSF1Ri remain uncertain.
Common Questions
What is Tenosynovial Giant Cell Tumour?
Tenosynovial Giant Cell Tumour (TGCT) is a rare, locally aggressive tumour arising from the synovial tissue of joints, tendon sheaths, and bursae. It occurs in two subtypes: localised (a tumour with a distinct, contained boundary) and diffuse (infiltrative growth without a clear boundary, which can destroy surrounding cartilage and bone). The diffuse subtype frequently recurs after surgery. Targeted therapies blocking the CSF1/CSF1R pathway have become an important treatment option for disease that cannot be fully removed surgically.
How many clinical trials are available for Tenosynovial Giant Cell Tumour?
RareWays currently indexes 24 clinical trials for Tenosynovial Giant Cell Tumour, of which 5 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Tenosynovial Giant Cell Tumour come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Tenosynovial Giant Cell Tumour.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.